pre-IPO PHARMA
COMPANIES
VC
JOBS
NEWS
CONTACT
Close ×
COMPANIES
VC
JOBS
NEWS
CONTACT
COMPANY OVERVIEW
WUGEN INC. IS A BIOTECHNOLOGY COMPANY DEVELOPING A NOVEL CAR-T THERAPY PLATFORM INCLUDING AN “OFF-THE-SHELF” FRATRICIDE-RESISTANT CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES.
LOCATION
St. Louis, MO, USA
Brisbane, CA, USA
THERAPEUTIC AREAS
Oncology
WEBSITE
https://wugen.com
CAREER WEBSITE
https://wugen.com/careers/
SOCIAL MEDIA
INVESTORS
PRESS RELEASES
Aug 15, 2023
Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
Jun 9, 2023
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress
May 11, 2023
Wugen Announces Multiple Presentations at the European Hematology Association (EHA) 2023 Congress
May 10, 2023
Wugen Appoints Industry Leader Mark Alles as Chair of the Board of Directors
Apr 19, 2023
Wugen Presents New Preclinical Data Reinforcing Anti-Tumor Functionality of WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023
For More Press Releases